

Supplemental Information

DETAILS ON STATISTICAL ANALYSIS

We used the `lm` function in R to fit a linear regression model with the following terms: continuous month (numbered 1–84, with 1 = January 2016 and 84 = December 2022), post (an indicator that equaled 0 if the month was ≤ 51 [March 2020] and 1 otherwise), and number of months after March 2020 (coded as 0 for months 1–51, 1 for month 52, 2 for month 53, and so on). We calculated confidence intervals using the `coefci` function, setting `vcov = NeweyWest`

with the appropriate number of lags. We selected the appropriate number of lags using `actest` in Stata, which reports results from the Cumby-Huizenga test for autocorrelation. To calculate the difference between the observed and predicted counterfactual value of outcomes in December 2022, we fitted a linear regression model using data from January 2016 through March 2020, then extrapolated this fitted line to December 2022 to calculate the predicted counterfactual value.

SUPPLEMENTAL TABLE 3 List of Antidepressant Medications Included in IQVIA's Market Definition of Antidepressants		
Uniform System of Classification 5 Category	Product Name	Molecule
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	CELEXA	CITALOPRAM
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	CITALOPRAM HBR	CITALOPRAM
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	ESCITALOPRAM OXAL	ESCITALOPRAM
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	FLUOXETINE HCL	FLUOXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	FLUOXETINE HCL	FLUOXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	FLUVOXAMINE MAL	FLUVOXAMINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	FLUVOXAMINE MAL ER	FLUVOXAMINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	LEXAPRO	ESCITALOPRAM
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	LUVOX CR	FLUVOXAMINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PAROXETINE CR	PAROXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PAROXETINE HCL	PAROXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PAROXETINE HCL ER	PAROXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PAXIL	PAROXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PAXIL CR	PAROXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PEXEVA	PAROXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PROZAC	FLUOXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	PROZAC WEEKLY	FLUOXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	RAPIFLUX	FLUOXETINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	SERTRALINE HCL	SERTRALINE
64340 SELECTIVE SEROTONIN REUPTAKE INHIBITORS	ZOLOFT	SERTRALINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	CYMBALTA	DULOXETINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	DESVENLAFAXIN SUC ER	DESVENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	DESVENLAFAXINE ER	DESVENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	DESVENLAFAXINE FUM ER	DESVENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	DRIZALMA	DULOXETINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	DULOXETINE HCL	DULOXETINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	EFFEXOR	VENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	EFFEXOR XR	VENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	FETZIMA	LEVOMILNACIPRAN
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	IRENKA	DULOXETINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	KHEDEZLA ER	DESVENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	PRISTIQ	DESVENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	VENLAFAXINE HCL	VENLAFAXINE
64350 SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS	VENLAFAXINE HCL ER	VENLAFAXINE
64310 TRICYCLICS & TETRACYCLICS	ADAPIN	DOXEPIN
64310 TRICYCLICS & TETRACYCLICS	AMITRIPTYLINE HCL	AMITRIPTYLINE
64310 TRICYCLICS & TETRACYCLICS	AMOXAPINE	AMOXAPINE
64310 TRICYCLICS & TETRACYCLICS	ANAFRANIL	CLOMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	CLOMIPRAMINE HCL	CLOMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	DESIPRAMINE HCL	DESIPRAMINE

SUPPLEMENTAL TABLE 3 Continued

Uniform System of Classification 5 Category	Product Name	Molecule
64310 TRICYCLICS & TETRACYCLICS	DOXEPIN HCL	DOXEPIN
64310 TRICYCLICS & TETRACYCLICS	ELAVIL	AMITRIPTYLINE
64310 TRICYCLICS & TETRACYCLICS	IMIPRAMINE HCL	IMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	IMIPRAMINE PAM	IMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	MAPROTILINE HCL	MAPROTILINE
64310 TRICYCLICS & TETRACYCLICS	MIRTAZAPINE	MIRTAZAPINE
64310 TRICYCLICS & TETRACYCLICS	NORPRAMIN	DESIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	NORTRIPTYLINE HCL	NORTRIPTYLINE
64310 TRICYCLICS & TETRACYCLICS	PAMELOR	NORTRIPTYLINE
64310 TRICYCLICS & TETRACYCLICS	PROTRIPTYLINE HCL	PROTRIPTYLINE
64310 TRICYCLICS & TETRACYCLICS	REMERON	MIRTAZAPINE
64310 TRICYCLICS & TETRACYCLICS	REMERON SOLTAB	MIRTAZAPINE
64310 TRICYCLICS & TETRACYCLICS	SURMONTIL	TRIMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	TOFRANIL	IMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	TOFRANIL-PM	IMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	TRIMIPRAMINE MAL	TRIMIPRAMINE
64310 TRICYCLICS & TETRACYCLICS	VIVACTIL	PROTRIPTYLINE
64320 MAO INHIBITORS	EMSAM	SELEGILINE
64320 MAO INHIBITORS	MARPLAN	ISOCARBOXAZID
64320 MAO INHIBITORS	NARDIL	PHENELZINE
64320 MAO INHIBITORS	PARNATE	TRANLYCYPROMINE
64320 MAO INHIBITORS	PHENELZINE SULF	PHENELZINE
64320 MAO INHIBITORS	TRANLYCYPRO SULF	TRANLYCYPROMINE
64330 NEWER GENERATION ANTIDEPRESSANTS	APLENZIN	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	BUDEPRION SR	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	BUDEPRION XL	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	BUPROPION HCL	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	BUPROPION HCL SR	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	BUPROPION HCL SR W	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	BUPROPION HCL XL	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	DESYREL	TRAZODONE
64330 NEWER GENERATION ANTIDEPRESSANTS	FORFIVO XL	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	NEFAZODONE HCL	NEFAZODONE
64330 NEWER GENERATION ANTIDEPRESSANTS	OLEPTRO	TRAZODONE
64330 NEWER GENERATION ANTIDEPRESSANTS	SERZONE	NEFAZODONE
64330 NEWER GENERATION ANTIDEPRESSANTS	TRAZAMINE	AMINOACIDS!HERBAL!TRAZODONE
64330 NEWER GENERATION ANTIDEPRESSANTS	TRAZODONE HCL	TRAZODONE
64330 NEWER GENERATION ANTIDEPRESSANTS	WELLBUTRIN	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	WELLBUTRIN SR	BUPROPION
64330 NEWER GENERATION ANTIDEPRESSANTS	WELLBUTRIN XL	BUPROPION
64360 SSRI/5HT PARTIAL AGONIST	TRINTELLIX	VORTIOXETINE
64360 SSRI/5HT PARTIAL AGONIST	VIIBRYD	VILAZODONE
64380 ANTIDEPRESSANTS IN COMBINATION	AMITRIPT/CHLORDIAZ	AMITRIPTYLINE!CHLORDIAZEPOXIDE
64380 ANTIDEPRESSANTS IN COMBINATION	LIMBITROL	AMITRIPTYLINE!CHLORDIAZEPOXIDE
64380 ANTIDEPRESSANTS IN COMBINATION	LIMBITROL DS	AMITRIPTYLINE!CHLORDIAZEPOXIDE
64380 ANTIDEPRESSANTS IN COMBINATION	PERPHENAZN/AMITRIP	AMITRIPTYLINE!PERPHENAZINE
64390 ANTIDEPRESSANTS, OTHER	SPRAVATO	ESKETAMINE
64390 ANTIDEPRESSANTS, OTHER	ZULRESSO	BREXANOLONE

The market definition included all drugs listed in Uniform System of Classification 3 64300.

SUPPLEMENTAL TABLE 4 Details on Population Denominators

Denominator	2016	2017	2018	2019	2020	2021	2022
Overall, 12–25 y	61 149 752	60 817 820	60 507 119	60 318 753	60 126 619	60 072 320	60 018 070
Females, 12–17 y	12 459 613	12 473 563	12 450 688	12 465 217	12 766 322	12 768 948	12 771 575
Males, 12–17 y	12 993 548	13 002 130	12 973 870	12 992 362	13 373 532	13 383 830	13 394 136
Females, 18–25 y	17 558 284	17 389 427	17 278 924	17 193 285	16 806 052	16 775 204	16 744 413
Males, 18–25 y	18 138 307	17 952 700	17 803 637	17 667 889	17 180 713	17 144 338	17 108 040
Females, Northeast	5 090 346	5 038 757	4 985 504	4 926 442	4 977 505	4 910 926	4 845 238
Females, Midwest	6 399 744	6 352 329	6 300 310	6 263 535	6 240 673	6 225 157	6 209 680
Females, South	11 371 671	11 352 254	11 346 802	11 380 448	11 328 255	11 403 153	11 478 546
Females, West	7 156 136	7 119 650	7 096 996	7 088 077	7 025 941	7 004 916	6 983 954
Males, Northeast	5 248 308	5 183 981	5 121 098	5 050 144	5 105 433	5 046 249	4 987 751
Males, Midwest	6 671 380	6 623 834	6 563 169	6 517 272	6 492 522	6 479 951	6 467 404
Males, South	11 720 387	11 703 904	11 681 234	11 700 614	11 632 903	11 700 241	11 767 969
Males, West	7 491 781	7 443 111	7 412 006	7 392 221	7 323 387	7 301 727	7 280 131

Data derived from the US Census Bureau's estimates of the civilian US population from 2016 to 2021. To impute population denominators for 2022, we calculated the year-over-year change between 2020 and 2021 and multiplied the 2021 denominator by this quantity. The 2016 to 2019 Census estimates were based on the 2010 Census, whereas the 2020 to 2021 estimates were based on the 2020 Census. The 2016 to 2019 estimates may have underestimated the US population relative to estimates from the 2020 Census. For example, on the basis of the 2010 Census, the number of US individuals aged 12 to 25 years as of July 2020 was estimated to be 59 125 612, but on the basis of the 2020 Census, this same number was estimated to be 60 126 619 (1.01693018 times higher). Accordingly, we multiplied 2016 to 2019 denominators by 1.01693018 to avoid an artificial abrupt jump in population denominators between 2019 and 2020. The table reveals the denominators used in the analysis.

SUPPLEMENTAL TABLE 5 Sensitivity Analysis: Association Between the COVID-19 Outbreak and the Monthly Number of Adolescents and Young Adults With ≥ 1 Dispensed Antidepressant Prescription

Group	Intercept [95% CI]	Slope Before March 2020 [95% CI]	Level Change in March 2020 [95% CI]	Slope Change After March 2020 [95% CI]	Slope After March 2020 [95% CI]	Observed Minus Predicted Number in December 2022 (% Difference)
Overall, 12–25 y	1 649 326.8 [1 618 200.1 to 1 680 453.6]	9629.1 [8490.7 to 10 767.5]	−23 339.0 [−93 125.0 to 46 447.0]	6877.3 [3328.2 to 10 426.4]	16 506.4 [13 093.3 to 19 919.5]	113 492.5 (4.6%)
Sex/age group						
Females, 12–17 y	315 367.1 [302 386.7 to 328 347.6]	2274.2 [1777.9 to 2770.5]	−15 114.1 [−42 756.9 to 12 528.7]	2976.0 [1858.3 to 4093.7]	5250.2 [4205.6 to 6294.8]	75 337.9 (14.9%)
Males, 12–17 y	236 348.1 [231 353.0 to 241 343.2]	1166.3 [972.0 to 1360.7]	−22 542.2 [−35 254.0 to −9830.5]	159.3 [−305.5 to 624.1]	1325.6 [858.5 to 1792.7]	−16 362.7 (−4.9%)
Females, 18–25 y	731 301.1 [715 903.5 to 746 698.7]	4427.7 [3871.3 to 4984.1]	23 348.3 [−12 568.1 to 59 264.7]	2938.1 [984.6 to 4891.7]	7365.8 [5447.5 to 9284.1]	60 717.2 (5.5%)
Males, 18–25 y	361 621.6 [356 237.2 to 367 006.1]	1774.7 [1580.6 to 1968.8]	−5643.2 [−17 565.8 to 6279.4]	795.0 [63.1 to 1526.9]	2569.7 [1847.6 to 3291.9]	−3065.2 (−0.6%)
Sex/region						
Females, Northeast	208 199.5 [202 989.6 to 213 409.5]	965.1 [772.2 to 1158.1]	−3500.5 [−14 514.2 to 7513.2]	1233.0 [687.8 to 1778.2]	2198.1 [1686.2 to 2710.1]	27 983.8 (9.7%)
Females, Midwest	282 213.5 [275 378.6 to 289 048.3]	1995.3 [1738.4 to 2252.3]	−1662.5 [−18 791.5 to 15 466.5]	1157.8 [305.9 to 2009.7]	3153.1 [2332.6 to 3973.7]	17 556.1 (3.9%)
Females, South	372 143.6 [363 424.7 to 380 862.6]	2406.0 [2135.0 to 2676.9]	5377.4 [−10 937.0 to 21 691.9]	2561.0 [1714.5 to 3407.6]	4967.0 [4144.4 to 5789.6]	64 575.4 (11.2%)
Females, West	184 111.6 [180 394.0 to 187 829.2]	1335.5 [1192.8 to 1478.1]	8019.7 [−2357.2 to 18 396.7]	962.3 [475.5 to 1449.1]	2297.7 [1815.2 to 2780.3]	25 939.9 (8.8%)
Males, Northeast	120 367.2 [118 305.6 to 122 428.9]	461.9 [380.6 to 543.3]	−8202.3 [−12 976.8 to −3427.8]	192.0 [8.8 to 375.2]	654.0 [471.3 to 836.6]	−4422.2 (−2.8%)
Males, Midwest	157 837.5 [154 887.0 to 160 788.0]	869.6 [758.7 to 980.6]	−7923.6 [−14 269.7 to −1577.6]	121.3 [−191.7 to 434.2]	990.9 [692.1 to 1289.7]	−11 859.3 (−5.1%)
Males, South	209 949.0 [206 197.1 to 213 700.8]	1020.1 [898.6 to 1141.5]	−8778.0 [−15 458.9 to −2097.0]	596.8 [261.8 to 931.8]	1616.9 [1304.9 to 1928.9]	2656.2 (0.9%)
Males, West	109 816.0 [108 796.3 to 110 835.8]	589.4 [547.5 to 631.4]	−3281.5 [−6177.5 to −385.5]	44.2 [−108.7 to 197.0]	633.6 [482.2 to 785.0]	−5802.6 (−3.6%)

SUPPLEMENTAL TABLE 6 Sensitivity Analysis: Association Between the COVID-19 Outbreak and Monthly Total Days Supplied of Antidepressant Prescriptions Dispensed to Adolescents and Young Adults per 100 000 People

Group	Intercept [95% CI]	Slope Before March 2020 [95% CI]	Level Change in March 2020 [95% CI]	Slope Change After March 2020 [95% CI]	Slope After March 2020 [95% CI]	Observed Minus Predicted Number of d Supplied in December 2022 (% Difference)
Overall, 12–25 y	110 072.8 [107 791.0 to 112 354.6]	1085.0 [985.7 to 1184.4]	3297.4 [–3431.4 to 10 026.3]	589.0 [327.7 to 850.2]	1674.0 [1411.7 to 1936.3]	18 305.1 (9.1%)
Sex/age group						
Females, 12–17 y	102 025.0 [97 152.2 to 106 897.7]	959.7 [755.0 to 1164.5]	–4851.8 [–15 255.6 to 5552.0]	1097.4 [717.6 to 1477.3]	2057.2 [1713.6 to 2400.7]	31 235.8 (17.1%)
Males, 12–17 y	72 337.8 [70 852.4 to 73 823.3]	499.3 [434.0 to 564.6]	–6891.5 [–11 497.0 to –2285.9]	52.5 [–86.0 to 191.0]	551.8 [400.7 to 702.9]	–3646.3 (–3.2%)
Females, 18–25 y	171 581.6 [168 441.3 to 174 722.0]	1955.8 [1808.2 to 2103.4]	19 516.7 [8824.8 to 30 208.5]	999.7 [517.0 to 1482.4]	2955.5 [2472.8 to 3438.2]	40 419.9 (12.0%)
Males, 18–25 y	81 617.9 [80 246.1 to 82 989.7]	787.7 [724.7 to 850.7]	4586.1 [–27.7 to 9199.9]	239.6 [25.9 to 453.3]	1027.3 [813.6 to 1241.0]	7654.8 (5.2%)
Sex/region						
Females, Northeast	170 827.0 [167 090.0 to 174 563.9]	1623.7 [1452.5 to 1794.9]	404.8 [–9445.6 to 10 255.2]	1379.6 [966.4 to 1792.7]	3003.3 [2611.6 to 3394.9]	40 597.9 (13.2%)
Females, Midwest	182 900.5 [179 268.6 to 186 532.5]	2149.6 [1974.5 to 2324.6]	7288.3 [–3991.9 to 18 568.6]	1144.4 [619.3 to 1669.5]	3293.9 [2798.2 to 3789.7]	34 294.4 (9.4%)
Females, South	132 078.9 [128 701.3 to 135 456.4]	1368.7 [1233.0 to 1504.3]	9397.0 [2880.1 to 15 914.0]	938.0 [645.8 to 1230.1]	2306.6 [2051.1 to 2562.2]	34 216.4 (13.9%)
Females, West	104 152.0 [102 339.8 to 105 964.3]	1163.1 [1079.9 to 1246.4]	10 736.2 [4570.3 to 16 902.2]	889.4 [575.0 to 1203.7]	2052.5 [1748.7 to 2356.3]	34 200.6 (16.9%)
Males, Northeast	94 139.9 [92 493.3 to 95 786.5]	777.9 [704.2 to 851.7]	–4946.2 [–11 009.5 to 1117.1]	171.2 [–49.8 to 392.3]	949.2 [714.9 to 1183.4]	–661.9 (–0.4%)
Males, Midwest	96 814.7 [95 066.9 to 98 562.6]	906.3 [831.4 to 981.1]	–1682.3 [–7469.4 to 4104.8]	162.6 [–71.0 to 396.1]	1068.9 [830.6 to 1307.1]	–267.5 (–0.2%)
Males, South	71 725.4 [70 260.3 to 73 190.5]	577.9 [522.3 to 633.6]	353.2 [–3603.3 to 4309.8]	173.7 [15.7 to 331.7]	751.6 [592.9 to 910.3]	4209.7 (3.5%)
Males, West	58 798.6 [57 785.2, 59 812.0]	512.7 [469.0 to 556.5]	1065.2 [–2269.0 to 4399.4]	109.3 [–21.7 to 240.3]	622.0 [487.9 to 756.1]	3528.3 (3.5%)

SUPPLEMENTAL TABLE 7 Sensitivity Analysis: Association Between the COVID-19 Outbreak and the Monthly Number of Adolescents and Young Adults With ≥ 1 Dispensed Antidepressant Prescription per 100 000 People, Controlling for Quarter

Group	Intercept [95% CI]	Slope Before March 2020 [95% CI]	Level Change in March 2020 [95% CI]	Slope Change After March 2020 [95% CI]	Slope After March 2020 [95% CI]	Observed Minus Predicted Rate in December 2022 (% Difference)
Overall, 12–25 y	2678.2 [2618.1 to 2738.4]	16.7 [15.2 to 18.1]	−17.9 [−130.1 to 94.3]	10.3 [4.0 to 16.6]	27.5 [22.3 to 32.6]	239.5 (5.9%)
Sex/age group						
Females, 12–17 y	2410.9 [2335.8 to 2486.1]	16.5 [14.8 to 18.2]	−113.8 [−280.7 to 53.2]	21.2 [12.9 to 29.5]	37.9 [30.1 to 45.7]	781.3 (20.7%)
Males, 12–17 y	1804.2 [1765.0 to 1843.5]	8.4 [7.3 to 9.5]	−204.9 [−296.7 to −113.1]	0.6 [−2.6 to 3.8]	9.1 [5.8 to 12.4]	−122.3 (−4.9%)
Females, 18–25 y	4181.4 [4060.9 to 4301.8]	28.6 [25.3 to 31.9]	233.2 [34.4 to 432.0]	16.2 [4.9 to 27.4]	45.8 [36.9 to 54.8]	436.3 (6.7%)
Males, 18–25 y	2011.2 [1963.8 to 2058.6]	11.9 [10.7 to 13.2]	9.2 [−49.7 to 68.0]	4.0 [0.3 to 7.6]	16.3 [13.5 to 19.2]	−27.2 (−0.9%)
Sex/region						
Females, Northeast	4031.0 [3919.7 to 4142.3]	22.3 [18.8 to 25.8]	−123.9 [−348.4 to 100.5]	27.2 [15.3 to 39.1]	50.6 [41.5 to 59.7]	719.2 (12.3%)
Females, Midwest	4372.4 [4251.9 to 4492.8]	33.7 [30.4 to 37.1]	17.4 [−235.5 to 270.3]	16.4 [2.5 to 30.4]	51.0 [39.4 to 62.7]	382.6 (5.4%)
Females, South	3232.8 [3148.4 to 3317.1]	20.5 [18.6 to 22.4]	108.7 [−34.0 to 251.4]	18.9 [10.8 to 26.9]	39.9 [33.3 to 46.5]	647.9 (13.2%)
Females, West	2535.5 [2479.5 to 2591.5]	19.2 [17.9 to 20.4]	156.6 [25.1 to 288.1]	13.5 [6.1 to 20.9]	33.2 [26.6 to 39.8]	503.8 (12.3%)
Males, Northeast	2282.0 [2230.0 to 2334.1]	11.3 [9.6 to 13.0]	−206.4 [−307.9 to −104.9]	4.2 [0.5 to 7.9]	16.0 [13.1 to 19.0]	−99.6 (−3.1%)
Males, Midwest	2385.4 [2331.7 to 2439.0]	14.9 [13.5 to 16.3]	−120.9 [−207.2 to −34.5]	0.9 [−3.3 to 5.1]	16.2 [12.7 to 19.7]	−229.8 (−6.4%)
Males, South	1797.6 [1754.2 to 1841.0]	8.8 [7.8 to 9.8]	−58.2 [−113.8 to −2.6]	3.8 [0.9 to 6.6]	12.8 [10.4 to 15.2]	8.3 (0.3%)
Males, West	1460.6 [1438.2 to 1483.0]	8.5 [8.0 to 9.0]	−31.2 [−71.0 to 8.7]	0.5 [−1.8 to 2.8]	9.2 [7.1 to 11.2]	−53.6 (−2.5%)

SUPPLEMENTAL TABLE 8 Sensitivity Analysis: Association Between the COVID-19 Outbreak and the Monthly Number of Adolescents and Young Adults With ≥ 1 Dispensed Prescription for a Selective Serotonin Reuptake Inhibitor per 100 000 People

Group	Intercept [95% CI]	Slope Before March 2020 [95% CI]	Level Change in March 2020 [95% CI]	Slope Change After March 2020 [95% CI]	Slope After March 2020 [95% CI]	Observed Minus Predicted Rate in December 2022 (% Difference)
Overall, 12–25 y	1915.5 [1885.2 to 1945.8]	12.0 [10.8 to 13.2]	−20.0 [−116.9 to 76.9]	7.0 [1.9 to 12.1]	19.0 [13.9 to 24.0]	70.7 (2.4%)
Sex/age group						
Females, 12–17 y	1928.1 [1850.9 to 2005.2]	15.0 [11.9 to 18.0]	−126.9 [−305.8 to 52.0]	18.7 [11.4 to 26.0]	33.6 [26.7 to 40.5]	393.5 (12.4%)
Males, 12–17 y	1338.2 [1310.2 to 1366.3]	7.2 [6.1 to 8.4]	−169.8 [−249.9 to −89.6]	0.9 [−1.8 to 3.5]	8.1 [5.3 to 10.9]	−148.6 (−7.6%)
Females, 18–25 y	2915.6 [2863.5 to 2967.7]	18.2 [16.2 to 20.3]	170.4 [19.2 to 321.6]	8.6 [0.0 to 17.3]	26.9 [18.3 to 35.4]	152.4 (3.4%)
Males, 18–25 y	1333.1 [1310.7 to 1355.5]	7.6 [6.6 to 8.5]	19.0 [−37.2 to 75.2]	1.5 [−2.2 to 5.1]	9.0 [5.5 to 12.5]	−53.6 (−2.7%)
Sex/region						
Females, Northeast	2964.8 [2896.5 to 3033.1]	16.4 [13.8 to 19.0]	−87.9 [−271.1 to 95.3]	21.0 [11.4 to 30.6]	37.4 [28.1 to 46.8]	395.5 (9.1%)
Females, Midwest	3182.3 [3116.5 to 3248.1]	24.0 [21.5 to 26.5]	−1.8 [−196.4 to 192.7]	10.1 [1.0 to 19.3]	34.1 [25.0 to 43.3]	44.6 (0.9%)
Females, South	2339.3 [2285.0 to 2393.5]	14.8 [12.8 to 16.7]	59.4 [−75.6 to 194.5]	13.9 [7.2 to 20.7]	28.7 [22.1 to 35.3]	325.0 (9.1%)
Females, West	1841.6 [1808.3 to 1874.8]	13.8 [12.5 to 15.0]	94.0 [−18.6 to 206.7]	8.8 [3.2 to 14.5]	22.6 [16.9 to 28.3]	204.4 (6.8%)
Males, Northeast	1646.8 [1619.1 to 1674.5]	8.6 [7.4 to 9.8]	−149.2 [−233.4 to −64.9]	2.7 [−0.7 to 6.0]	11.2 [7.7 to 14.7]	−128.8 (−5.4%)
Males, Midwest	1659.2 [1627.4 to 1691.0]	10.5 [9.3 to 11.7]	−79.4 [−158.2 to −0.7]	−0.3 [−4.3 to 3.7]	10.2 [6.2 to 14.1]	−199.2 (−7.8%)
Males, South	1224.5 [1207.1 to 1241.9]	6.2 [5.5 to 6.9]	−44.8 [−89.6 to 0.0]	2.4 [0.0 to 4.8]	8.6 [6.4 to 10.9]	−30.1 (−1.7%)
Males, West	1000.4 [991.8 to 1008.9]	6.0 [5.7 to 6.4]	−26.0 [−59.8 to 7.7]	−0.3 [−2.3 to 1.7]	5.7 [3.8 to 7.7]	−89.4 (−5.9%)

SUPPLEMENTAL TABLE 9 Difference Between the Observed Outcome and the Outcome Predicted by the Counterfactual Trend in December 2022 in the Main Analysis and the 4 Sensitivity Analyses

Group	Main Analysis: Monthly No. Individuals With ≥ 1 Dispensed Antidepressant Prescription per 100 000 People	Sensitivity Analysis: Monthly No. Individuals With ≥ 1 Dispensed Antidepressant Prescription	Sensitivity Analysis: Monthly Total d Supplied in Dispensed Antidepressant Prescriptions per 100 000 People	Sensitivity analysis: monthly No. Individuals With ≥ 1 Dispensed Antidepressant Prescription per 100 000 People, Controlling for Quarter	Sensitivity Analysis: Monthly No. Individuals With ≥ 1 Dispensed Prescription for a Selective Serotonin Reuptake Inhibitor per 100 000 People
Overall, 12–25 y	166.7 (4.0%)	113 492.5 (4.6%)	18 305.1 (9.1%)	239.5 (5.9%)	70.7 (2.4%)
Sex/age group					
Females, 12–17 y	514.6 (12.7%)	75 337.9 (14.9%)	31 235.8 (17.1%)	781.3 (20.7%)	393.5 (12.4%)
Males, 12–17 y	–182.2 (–7.1%)	–16 362.7 (–4.9%)	–3646.3 (–3.2%)	–122.3 (–4.9%)	–148.6 (–7.6%)
Females, 18–25 y	403.8 (6.2%)	60 717.2 (5.5%)	40 419.9 (12.0%)	436.3 (6.7%)	152.4 (3.4%)
Males, 18–25 y	0.1 (0.0%)	–3065.2 (–0.6%)	7654.8 (5.2%)	–27.2 (–0.9%)	–53.6 (–2.7%)
Sex/region					
Females, Northeast	559.5 (9.3%)	27 983.8 (9.7%)	40 597.9 (13.2%)	719.2 (12.3%)	395.5 (9.1%)
Females, Midwest	238.7 (3.3%)	17 556.1 (3.9%)	34 294.4 (9.4%)	382.6 (5.4%)	44.6 (0.9%)
Females, South	511.3 (10.1%)	64 575.4 (11.2%)	34 216.4 (13.9%)	647.9 (13.2%)	325.0 (9.1%)
Females, West	397.0 (9.4%)	25 939.9 (8.8%)	34 200.6 (16.9%)	503.8 (12.3%)	204.4 (6.8%)
Males, Northeast	–127.9 (–4.0%)	–4422.2 (–2.8%)	–661.9 (–0.4%)	–99.6 (–3.1%)	–128.8 (–5.4%)
Males, Midwest	–217.4 (–6.0%)	–11 859.3 (–5.1%)	–267.5 (–0.2%)	–229.8 (–6.4%)	–199.2 (–7.8%)
Males, South	–1.3 (–0.1%)	2656.2 (0.9%)	4209.7 (3.5%)	8.3 (0.3%)	–30.1 (–1.7%)
Males, West	–72.9 (–3.3%)	–5802.6 (–3.6%)	3528.3 (3.5%)	–53.6 (–2.5%)	–89.4 (–5.9%)